公开(公告)号：US20070155781A1

公开(公告)日：2007-07-05

申请号：US11604677

申请日：2006-11-28

申请人： David Garvey ,  L. Letts ,  H. Renfroe ,  Stewart Richardson

发明人： David Garvey ,  L. Letts ,  H. Renfroe ,  Stewart Richardson

IPC分类号： A61K31/46 ,  C07D451/02

CPC分类号： C07D451/06 ,  C07C313/36 ,  C07D311/22 ,  C07D451/10 ,  C07D471/04 ,  C07J5/00 ,  C07J7/00 ,  C07J31/00 ,  C07J71/00 ,  C07J71/0031

摘要： Disclosed are (i) compounds of a steroid, a β-agonist, an anticholinergic, a mast cell stabilizer and a phosphodiesterase (PDE) inhibitor directly or indirectly linked to a NO or NO2 group or a group which stimulates endogenous production of NO or EDRF in vivo; (ii) compositions of steroids, β-agonists, anticholinergics, mast cell stabilizers and PDE inhibitors, which can optionally be substituted with at least one NO or NO2 moiety or a group which stimulates endogenous production of NO or EDRF in vivo, and a compound that donates, transfers or releases nitric oxide as a charged species, i.e., nitrosonium (NO+) or nitroxyl (NO−), or as the neutral species, nitric oxide (NO.) or that stimulates endogenous production of NO or EDRF in vivo; and (iii) uses for them in preventing and/or treating respiratory disorders.

摘要翻译： 公开的是（i）直接或间接连接到NO或NO 2基团或基团上的基团的类固醇，β-激动剂，抗胆碱能药，肥大细胞稳定剂和磷酸二酯酶（PDE）抑制剂的化合物 其在体内刺激NO或EDRF的内源性产生; （ii）类固醇，β-激动剂，抗胆碱能药物，肥大细胞稳定剂和PDE抑制剂的组合物，其可任选地被至少一个NO或NO 2个部分取代，或刺激内源性产生NO 或EDRF，以及作为带电物质，即亚硝酸盐（硝酸）或硝酰基（NO +）的一氧化氮，或NOX + 作为中性物种，一氧化氮（NO））或者在体内刺激NO或EDRF的内源性产生; 和（iii）用于预防和/或治疗呼吸系统疾病。

公开(公告)号：US20070179195A1

公开(公告)日：2007-08-02

申请号：US11730886

申请日：2007-04-04

申请人： L. Letts ,  David Garvey

发明人： L. Letts ,  David Garvey

IPC分类号： A61K31/21 ,  C07C229/38

CPC分类号： C07D295/185 ,  A61K45/06 ,  C07C229/42 ,  C07C317/18 ,  C07C323/12 ,  C07D493/04

摘要： The invention provides novel nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) selective inhibitors and novel compositions and kits comprising at least one nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or, optionally, at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 selective inhibitors; for facilitating wound healing; for treating and/or preventing renal and/or respiratory toxicity; for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2; and for improving the cardiovascular profile of COX-2 selective inhibitors.

摘要翻译： 本发明提供新的亚硝化和/或亚硝基化的环氧合酶2（COX-2）选择性抑制剂和包含至少一种亚硝化和/或亚硝基化的环氧合酶2（COX-2）选择性抑制剂的新组合物和试剂盒，以及任选的至少一种化合物 捐赠，转移或释放一氧化氮，刺激一氧化氮的内源性合成，提高内源性内皮水平的内源性松弛因子，或者是一氧化氮合酶的底物和/或任选的至少一种治疗剂。 本发明还提供了治疗炎症，疼痛和发烧的方法; 用于治疗和/或改善COX-2选择性抑制剂的胃肠性质; 促进伤口愈合; 用于治疗和/或预防肾和/或呼吸毒性; 用于治疗和/或预防由环氧合酶-2水平升高引起的其他疾病; 并用于改善COX-2选择性抑制剂的心血管外形。

公开(公告)号：US20050250758A1

公开(公告)日：2005-11-10

申请号：US11180790

申请日：2005-07-14

申请人： David Garvey ,  L. Letts ,  Chia-En Lin ,  Tiansheng Wang

发明人： David Garvey ,  L. Letts ,  Chia-En Lin ,  Tiansheng Wang

IPC分类号： C07D295/08 ,  A61K31/198 ,  A61K31/222 ,  A61K31/29 ,  A61K31/341 ,  A61K31/397 ,  A61K31/40 ,  A61K31/401 ,  A61K31/4164 ,  A61K31/426 ,  A61K31/445 ,  A61K31/4453 ,  A61K31/55 ,  A61K45/06 ,  A61P1/04 ,  A61P17/00 ,  A61P27/02 ,  A61P27/06 ,  A61P27/16 ,  A61P29/00 ,  A61P31/00 ,  A61P31/04 ,  A61P31/18 ,  C07D233/54 ,  C07D233/64 ,  C07D277/28 ,  C07D277/48 ,  C07D277/52 ,  C07D295/096 ,  C07D307/52

CPC分类号： C07D233/54 ,  C07D233/64 ,  C07D277/48 ,  C07D295/092 ,  C07D295/096

摘要： The invention describes novel nitrosated and/or nitrosylated H2 receptor antagonist compounds, and novel compositions comprising at least one H2 receptor antagonist compound that is optionally substituted with at least one NO and/or NO2 group, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase and/or at least one nonsteroidal antiinflammatory drug, antacid, bismuth-containing reagent or anti-viral agent. The invention also describes methods for treating and/or preventing gastrointestinal disorders; improving gastroprotective properties of H2 receptor antagonists; decreasing the recurrence of ulcers; facilitating ulcer healing; preventing and/or treating inflammations and microbial infections, ophthalmic diseases and disorders, multiple sclerosis, and viral infections; and decreasing or reducing the gastrointestinal toxicity associated with the use of nonsteroidal antiinflammatory compounds.

摘要翻译： 本发明描述了新的亚硝化和/或亚硝基化的H 2 O 2受体拮抗剂化合物，以及包含至少一种H 2受体拮抗剂化合物的新组合物，其任选被至少一个NO 和/或NO 2个基团，以及任选地，至少一种捐赠，转移或释放一氧化氮的化合物，刺激一氧化氮的内源性合成，提高内源性内皮水平的内源性松弛因子，或者是 一氧化氮合酶的底物和/或至少一种非甾体抗炎药，抗酸剂，含铋试剂或抗病毒剂。 本发明还描述了治疗和/或预防胃肠道疾病的方法; 改善H 2受体拮抗剂的胃保护性质; 减少溃疡复发; 促进溃疡愈合; 预防和/或治疗炎症和微生物感染，眼科疾病和病症，多发性硬化和病毒感染; 并减少或减少与使用非甾体抗炎化合物相关的胃肠道毒性。